US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Soligenix, Inc.

1.10

-0.0050-0.45%

Volume:96.95K

Turnover:105.43K

Market Cap:11.04M

PE:-0.32

High:1.13

Open:1.11

Low:1.07

Close:1.10

52wk High:6.23

52wk Low:1.02

Shares:10.09M

Float Shares:7.93M

Volume Ratio:0.99

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.3894

EPS(LYR):-4.9786

ROE:-165.10%

ROA:-69.38%

PB:1.45

PE(LYR):-0.22

Loading ...

Overview Company News Filings

Soligenix Inc. Publishes 2026 Shareholder Letter

Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX)

Soligenix : Continue to Evaluate Potential Strategic Options, Including, but Not Limited to, Partnership and Merger and Acquisition Opportunities

THOMSON REUTERS

Soligenix Advances Phase 3 FLASH2 Trial for HyBryte in Cutaneous T-Cell Lymphoma

Soligenix Reports Progress on HyBryte Phase 3 Trial and Outlines 2026 Milestones

BRIEF-Soligenix Inc Enters Sales Agreement With Rodman

Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation

Soligenix Reports Positive Phase 2 Results for SGX945 in Behçet's Disease

Soligenix Inc - Sgx945 Well-Tolerated With No Treatment-Related Adverse Events

THOMSON REUTERS

Positive Clinical Results From Phase 2 Trial of Sgx945 for the Treatment of BehÇEt's Disease Published in Rheumatology (Oxford)

THOMSON REUTERS

Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302

Soligenix Reports Positive Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis

Soligenix Inc - Study Confirms Sgx302 Improves Psoriasis Lesions

THOMSON REUTERS

Soligenix Inc - Optimized Gel Formulation Shows Success in Third Cohort

THOMSON REUTERS

Soligenix Announces Top-Line Results of the Phase 2a Study of Sgx302 (Synthetic Hypericin) in Patients With Mild-to-Moderate Psoriasis

THOMSON REUTERS

Soligenix Inc - Sgx302 Gel Therapy Well Tolerated With No Adverse Events

THOMSON REUTERS

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNGX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNGX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","market":"US","secType":"STK","nameCN":"Soligenix, Inc.","latestPrice":1.095,"timestamp":1771875332758,"preClose":1.1,"halted":0,"volume":96953,"delay":0,"changeRate":-0.00454545454545465,"floatShares":7928900,"shares":10086130,"eps":-3.389437,"marketStatus":"Trading","change":-0.005,"latestTime":"02-23 14:44:42 EST","open":1.11,"high":1.125,"low":1.07,"amount":105430.98721790001,"amplitude":0.05,"askPrice":1.1,"askSize":200,"bidPrice":1.09,"bidSize":648,"shortable":3,"etf":0,"ttmEps":-3.389437,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.1316,"preClose":1.1,"latestTime":"09:08 EST","volume":4161,"amount":4743.5458254000005,"timestamp":1771855685763,"change":0.0316,"changeRate":0.028727,"amplitude":0.116273},"postHourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"19:49 EST","volume":104,"amount":114.4,"timestamp":1771634951580,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.986366},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","floatShares":7928900,"roa":"-69.38%","roe":"-165.10%","lyrEps":-4.978626,"volumeRatio":0.986366,"shares":10086130,"dividePrice":0,"high":1.125,"amplitude":0.05,"preClose":1.1,"low":1.07,"week52Low":1.02,"pbRate":"1.45","week52High":6.2299,"institutionHeld":0.088,"latestPrice":1.095,"committee":0.528302,"eps":-3.389437,"divideRate":0,"volume":96953,"delay":0,"ttmEps":-3.389437,"open":1.11,"prevYearClose":1.34,"prevWeekClose":1.1,"prevMonthClose":1.25,"prevQuarterClose":1.34,"fiveDayClose":1.09,"twentyDayClose":1.38,"sixtyDayClose":1.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNGX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-07","symbol":"SNGX","fiscalQuarterEnding":"2025/09","expectedEps":-0.63,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2025-08-14","symbol":"SNGX","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2025-05-09","symbol":"SNGX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":-1.06},{"market":"US","date":"2025-03-21","symbol":"SNGX","fiscalQuarterEnding":"2024/12","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742529600000,"reportTimeType":"pre","actualEps":-1.14},{"market":"US","date":"2024-11-08","symbol":"SNGX","fiscalQuarterEnding":"2024/09","expectedEps":-1.09,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":-0.78}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNGX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNGX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1752642000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNGX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNGX","date":"2026-02-20","current":-0.319581,"percent":0.608448,"low":-4.210471,"twenty":-2.339841,"median":-1.209806,"eighty":-0.616672,"high":-0.277411,"avg":-1.512098,"sd":0.990104,"marketCap":11195604},"quantilePoints":[{"date":"2021-02-26","current":-3.458797,"twenty":-3.833505,"median":-3.03163,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-03-05","current":-3.207248,"twenty":-3.835264,"median":-3.031519,"eighty":-2.11619,"marketCap":48172598},{"date":"2021-03-12","current":-3.75227,"twenty":-3.835264,"median":-3.03243,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-19","current":-3.75227,"twenty":-3.83612,"median":-3.040991,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-26","current":-3.270135,"twenty":-3.835838,"median":-3.042299,"eighty":-2.116451,"marketCap":49117159},{"date":"2021-04-01","current":-3.529516,"twenty":-3.826467,"median":-3.042299,"eighty":-2.116451,"marketCap":62431916},{"date":"2021-04-09","current":-3.41639,"twenty":-3.822157,"median":-3.042299,"eighty":-2.11619,"marketCap":60430892},{"date":"2021-04-16","current":-2.963888,"twenty":-3.822157,"median":-3.041843,"eighty":-2.11619,"marketCap":52426802},{"date":"2021-04-23","current":-3.212764,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":56829052},{"date":"2021-04-30","current":-3.258014,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":57629461},{"date":"2021-05-07","current":-2.896013,"twenty":-3.808915,"median":-3.033651,"eighty":-2.11619,"marketCap":51226187},{"date":"2021-05-14","current":-2.013634,"twenty":-3.807849,"median":-3.030979,"eighty":-2.11619,"marketCap":35618208},{"date":"2021-05-21","current":-3.342664,"twenty":-3.807849,"median":-3.034785,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-05-28","current":-3.278382,"twenty":-3.807849,"median":-3.042299,"eighty":-2.11619,"marketCap":40880324},{"date":"2021-06-04","current":-3.471227,"twenty":-3.807849,"median":-3.047644,"eighty":-2.11619,"marketCap":43285047},{"date":"2021-06-11","current":-3.792638,"twenty":-3.808915,"median":-3.051016,"eighty":-2.11619,"marketCap":47292924},{"date":"2021-06-18","current":-3.599792,"twenty":-3.815158,"median":-3.058506,"eighty":-2.11619,"marketCap":44888198},{"date":"2021-06-25","current":-3.696215,"twenty":-3.815158,"median":-3.073824,"eighty":-2.11619,"marketCap":46090561},{"date":"2021-07-02","current":-3.342664,"twenty":-3.814599,"median":-3.085535,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-07-09","current":-3.406946,"twenty":-3.820677,"median":-3.087545,"eighty":-2.11619,"marketCap":42483474},{"date":"2021-07-16","current":-3.149818,"twenty":-3.820677,"median":-3.091406,"eighty":-2.11619,"marketCap":39277173},{"date":"2021-07-23","current":-3.10032,"twenty":-3.820677,"median":-3.101159,"eighty":-2.11619,"marketCap":38659960},{"date":"2021-07-30","current":-3.063037,"twenty":-3.820677,"median":-3.120558,"eighty":-2.11619,"marketCap":38195046},{"date":"2021-08-06","current":-3.2141,"twenty":-3.820677,"median":-3.123123,"eighty":-2.11619,"marketCap":40078748},{"date":"2021-08-13","current":-3.271976,"twenty":-3.820677,"median":-3.12497,"eighty":-2.116451,"marketCap":37922108},{"date":"2021-08-20","current":-3.183049,"twenty":-3.820677,"median":-3.127219,"eighty":-2.128852,"marketCap":36891443},{"date":"2021-08-27","current":-3.529416,"twenty":-3.819297,"median":-3.140414,"eighty":-2.139444,"marketCap":40905829},{"date":"2021-09-03","current":-3.806233,"twenty":-3.819297,"median":-3.149818,"eighty":-2.140169,"marketCap":44114128},{"date":"2021-09-10","current":-4.013846,"twenty":-3.822057,"median":-3.152361,"eighty":-2.145333,"marketCap":46520354},{"date":"2021-09-17","current":-3.737029,"twenty":-3.822117,"median":-3.16435,"eighty":-2.145333,"marketCap":43312052},{"date":"2021-09-24","current":-3.546717,"twenty":-3.822117,"median":-3.180179,"eighty":-2.145333,"marketCap":41106347},{"date":"2021-10-01","current":-3.633222,"twenty":-3.822117,"median":-3.181533,"eighty":-2.145333,"marketCap":42108942},{"date":"2021-10-08","current":-3.59862,"twenty":-3.822117,"median":-3.189617,"eighty":-2.145333,"marketCap":41707904},{"date":"2021-10-15","current":-3.806233,"twenty":-3.822117,"median":-3.197852,"eighty":-2.150499,"marketCap":44114128},{"date":"2021-10-22","current":-3.494814,"twenty":-3.822117,"median":-3.211097,"eighty":-2.154035,"marketCap":40504791},{"date":"2021-10-29","current":-3.494814,"twenty":-3.822117,"median":-3.2141,"eighty":-2.161849,"marketCap":40504791},{"date":"2021-11-05","current":-3.42561,"twenty":-3.822117,"median":-3.220267,"eighty":-2.162699,"marketCap":39702715},{"date":"2021-11-12","current":-2.916544,"twenty":-3.822117,"median":-3.222002,"eighty":-2.170406,"marketCap":39044830},{"date":"2021-11-19","current":-2.741366,"twenty":-3.822117,"median":-3.218265,"eighty":-2.170406,"marketCap":36699653},{"date":"2021-11-26","current":-2.875872,"twenty":-3.822117,"median":-3.216049,"eighty":-2.170406,"marketCap":38500338},{"date":"2021-12-03","current":-2.562024,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":34298742},{"date":"2021-12-10","current":-2.446092,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":32746723},{"date":"2021-12-17","current":-2.394211,"twenty":-3.822117,"median":-3.211931,"eighty":-2.170406,"marketCap":32052174},{"date":"2021-12-23","current":-2.458582,"twenty":-3.822117,"median":-3.203637,"eighty":-2.170406,"marketCap":32913930},{"date":"2021-12-31","current":-2.114631,"twenty":-3.822117,"median":-3.191039,"eighty":-2.169084,"marketCap":28309324},{"date":"2022-01-07","current":-2.217909,"twenty":-3.822097,"median":-3.181959,"eighty":-2.166201,"marketCap":29691947},{"date":"2022-01-14","current":-2.069155,"twenty":-3.813481,"median":-3.181107,"eighty":-2.161849,"marketCap":27700521},{"date":"2022-01-21","current":-2.036489,"twenty":-3.810294,"median":-3.1662,"eighty":-2.161849,"marketCap":27263212},{"date":"2022-01-28","current":-1.97436,"twenty":-3.809605,"median":-3.158329,"eighty":-2.15359,"marketCap":26431467},{"date":"2022-02-04","current":-1.986209,"twenty":-3.809605,"median":-3.149818,"eighty":-2.148285,"marketCap":26590099},{"date":"2022-02-11","current":-2.014712,"twenty":-3.809605,"median":-3.144477,"eighty":-2.14007,"marketCap":26971673},{"date":"2022-02-18","current":-2.17772,"twenty":-3.809605,"median":-3.132783,"eighty":-2.139444,"marketCap":29153928},{"date":"2022-02-25","current":-2.306142,"twenty":-3.809605,"median":-3.129679,"eighty":-2.139444,"marketCap":30873154},{"date":"2022-03-04","current":-2.145054,"twenty":-3.809605,"median":-3.129679,"eighty":-2.138219,"marketCap":28716619},{"date":"2022-03-11","current":-2.312226,"twenty":-3.809605,"median":-3.124184,"eighty":-2.138219,"marketCap":30954613},{"date":"2022-03-18","current":-2.222556,"twenty":-3.806233,"median":-3.11997,"eighty":-2.138219,"marketCap":29754157},{"date":"2022-03-25","current":-2.309344,"twenty":-3.806233,"median":-3.105034,"eighty":-2.138219,"marketCap":30916027},{"date":"2022-04-01","current":-2.532554,"twenty":-3.806233,"median":-3.105034,"eighty":-2.139763,"marketCap":31786020},{"date":"2022-04-08","current":-2.529132,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":31743066},{"date":"2022-04-14","current":-2.481219,"twenty":-3.806233,"median":-3.105034,"eighty":-2.150636,"marketCap":31141708},{"date":"2022-04-22","current":-2.102362,"twenty":-3.806233,"median":-3.105034,"eighty":-2.152006,"marketCap":26386692},{"date":"2022-04-29","current":-1.80975,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":22714119},{"date":"2022-05-06","current":-1.772104,"twenty":-3.806233,"median":-3.105034,"eighty":-2.142794,"marketCap":22241624},{"date":"2022-05-13","current":-1.178605,"twenty":-3.806233,"median":-3.100739,"eighty":-2.140196,"marketCap":17133992},{"date":"2022-05-20","current":-1.543144,"twenty":-3.806233,"median":-3.091406,"eighty":-2.139444,"marketCap":22433476},{"date":"2022-05-27","current":-1.77383,"twenty":-3.806233,"median":-3.089475,"eighty":-2.129342,"marketCap":25787088},{"date":"2022-06-03","current":-1.514419,"twenty":-3.806233,"median":-3.087545,"eighty":-2.119815,"marketCap":22015888},{"date":"2022-06-10","current":-1.776792,"twenty":-3.806233,"median":-3.087545,"eighty":-2.115527,"marketCap":25830138},{"date":"2022-06-17","current":-1.687952,"twenty":-3.806233,"median":-3.087545,"eighty":-2.100887,"marketCap":24538630},{"date":"2022-06-24","current":-1.617473,"twenty":-3.806233,"median":-3.087545,"eighty":-2.092935,"marketCap":23514034},{"date":"2022-07-01","current":-1.719934,"twenty":-3.806233,"median":-3.087545,"eighty":-2.086976,"marketCap":25003573},{"date":"2022-07-08","current":-1.762281,"twenty":-3.806233,"median":-3.087545,"eighty":-2.078536,"marketCap":25619192},{"date":"2022-07-15","current":-2.025543,"twenty":-3.806233,"median":-3.087545,"eighty":-2.0727,"marketCap":29446357},{"date":"2022-07-22","current":-2.259783,"twenty":-3.806233,"median":-3.077014,"eighty":-2.0727,"marketCap":32851632},{"date":"2022-07-29","current":-2.592339,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":37686173},{"date":"2022-08-05","current":-2.679994,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":38960460},{"date":"2022-08-12","current":-2.539174,"twenty":-3.806233,"median":-3.068833,"eighty":-2.0727,"marketCap":38156702},{"date":"2022-08-19","current":-2.380834,"twenty":-3.793261,"median":-3.057725,"eighty":-2.0727,"marketCap":35777295},{"date":"2022-08-26","current":-2.280438,"twenty":-3.77381,"median":-3.037933,"eighty":-2.0727,"marketCap":34268616},{"date":"2022-09-02","current":-2.065302,"twenty":-3.75227,"median":-3.012696,"eighty":-2.072608,"marketCap":31035726},{"date":"2022-09-09","current":-1.986419,"twenty":-3.744873,"median":-2.99389,"eighty":-2.068643,"marketCap":29850333},{"date":"2022-09-16","current":-1.921878,"twenty":-3.736351,"median":-2.972351,"eighty":-2.06071,"marketCap":28880466},{"date":"2022-09-23","current":-1.455464,"twenty":-3.71974,"median":-2.963888,"eighty":-2.050413,"marketCap":21871566},{"date":"2022-09-30","current":-1.252663,"twenty":-3.703324,"median":-2.929273,"eighty":-2.049272,"marketCap":18824029},{"date":"2022-10-07","current":-1.641628,"twenty":-3.69525,"median":-2.907735,"eighty":-2.046565,"marketCap":24669091},{"date":"2022-10-14","current":-1.686663,"twenty":-3.686342,"median":-2.894033,"eighty":-2.042346,"marketCap":25345843},{"date":"2022-10-21","current":-1.804558,"twenty":-3.668494,"median":-2.865205,"eighty":-2.037717,"marketCap":27117466},{"date":"2022-10-28","current":-2.007933,"twenty":-3.667825,"median":-2.841668,"eighty":-2.029514,"marketCap":30173622},{"date":"2022-11-04","current":-1.893481,"twenty":-3.66653,"median":-2.8149,"eighty":-2.026959,"marketCap":28453728},{"date":"2022-11-11","current":-2.05165,"twenty":-3.663597,"median":-2.797124,"eighty":-2.021049,"marketCap":30259092},{"date":"2022-11-18","current":-1.905104,"twenty":-3.648917,"median":-2.778014,"eighty":-2.01711,"marketCap":28097730},{"date":"2022-11-25","current":-1.699939,"twenty":-3.641768,"median":-2.743928,"eighty":-2.014281,"marketCap":25071819},{"date":"2022-12-02","current":-1.64132,"twenty":-3.633222,"median":-2.735277,"eighty":-2.004814,"marketCap":24207273},{"date":"2022-12-09","current":-1.533755,"twenty":-3.633222,"median":-2.711283,"eighty":-1.996265,"marketCap":22620834},{"date":"2022-12-16","current":-1.846485,"twenty":-3.633222,"median":-2.682693,"eighty":-1.984215,"marketCap":27233184},{"date":"2022-12-23","current":-1.891329,"twenty":-3.633222,"median":-2.662821,"eighty":-1.97859,"marketCap":27894562},{"date":"2022-12-30","current":-1.32478,"twenty":-3.633222,"median":-2.64295,"eighty":-1.974296,"marketCap":19538728},{"date":"2023-01-06","current":-1.410357,"twenty":-3.630477,"median":-2.626074,"eighty":-1.970255,"marketCap":20800882},{"date":"2023-01-13","current":-1.377155,"twenty":-3.619207,"median":-2.596781,"eighty":-1.964148,"marketCap":20311194},{"date":"2023-01-20","current":-1.469416,"twenty":-3.619207,"median":-2.584653,"eighty":-1.961265,"marketCap":21671919},{"date":"2023-01-27","current":-1.409182,"twenty":-3.619207,"median":-2.562024,"eighty":-1.955717,"marketCap":20783547},{"date":"2023-02-03","current":-1.351886,"twenty":-3.615611,"median":-2.546439,"eighty":-1.950333,"marketCap":19938511},{"date":"2023-02-10","current":-1.047974,"twenty":-3.615611,"median":-2.539174,"eighty":-1.93629,"marketCap":15456214},{"date":"2023-02-17","current":-0.812914,"twenty":-3.615611,"median":-2.519549,"eighty":-1.920521,"marketCap":11989399},{"date":"2023-02-24","current":-0.744355,"twenty":-3.615611,"median":-2.50894,"eighty":-1.916691,"marketCap":10978245},{"date":"2023-03-03","current":-0.579814,"twenty":-3.615611,"median":-2.50315,"eighty":-1.905104,"marketCap":8551475},{"date":"2023-03-10","current":-0.628784,"twenty":-3.615611,"median":-2.498294,"eighty":-1.893481,"marketCap":9273728},{"date":"2023-03-17","current":-0.45249,"twenty":-3.615611,"median":-2.494874,"eighty":-1.873469,"marketCap":6673617},{"date":"2023-03-24","current":-0.360425,"twenty":-3.615611,"median":-2.490459,"eighty":-1.864593,"marketCap":5315782},{"date":"2023-03-31","current":-0.385889,"twenty":-3.614644,"median":-2.487664,"eighty":-1.852184,"marketCap":5691353},{"date":"2023-04-06","current":-0.368498,"twenty":-3.614644,"median":-2.487664,"eighty":-1.838884,"marketCap":5084661},{"date":"2023-04-14","current":-0.343373,"twenty":-3.615611,"median":-2.488267,"eighty":-1.81823,"marketCap":4737979},{"date":"2023-04-21","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.806924,"marketCap":4298921},{"date":"2023-04-28","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.796476,"marketCap":4298921},{"date":"2023-05-05","current":-0.486536,"twenty":-3.615611,"median":-2.488267,"eighty":-1.780665,"marketCap":6713384},{"date":"2023-05-12","current":-0.530952,"twenty":-3.615611,"median":-2.488267,"eighty":-1.774785,"marketCap":7326252},{"date":"2023-05-19","current":-0.450777,"twenty":-3.615611,"median":-2.488267,"eighty":-1.773356,"marketCap":4731101},{"date":"2023-05-26","current":-0.548639,"twenty":-3.615611,"median":-2.488267,"eighty":-1.762981,"marketCap":5758198},{"date":"2023-06-02","current":-0.556758,"twenty":-3.615611,"median":-2.488267,"eighty":-1.761231,"marketCap":5843414},{"date":"2023-06-09","current":-0.568435,"twenty":-3.615611,"median":-2.488267,"eighty":-1.758431,"marketCap":5965964},{"date":"2023-06-16","current":-0.553201,"twenty":-3.615611,"median":-2.488267,"eighty":-1.753075,"marketCap":5806081},{"date":"2023-06-23","current":-0.549104,"twenty":-3.616579,"median":-2.489363,"eighty":-1.755221,"marketCap":5763076},{"date":"2023-06-30","current":-0.549025,"twenty":-3.617546,"median":-2.490459,"eighty":-1.751843,"marketCap":5762256},{"date":"2023-07-07","current":-0.561243,"twenty":-3.617546,"median":-2.490459,"eighty":-1.719975,"marketCap":5890486},{"date":"2023-07-14","current":-0.534333,"twenty":-3.617546,"median":-2.490459,"eighty":-1.701031,"marketCap":5608055},{"date":"2023-07-21","current":-0.517398,"twenty":-3.617546,"median":-2.488267,"eighty":-1.696019,"marketCap":5430317},{"date":"2023-07-28","current":-0.487163,"twenty":-3.617546,"median":-2.48706,"eighty":-1.691433,"marketCap":5112988},{"date":"2023-08-04","current":-0.458552,"twenty":-3.617546,"median":-2.471478,"eighty":-1.68556,"marketCap":4812701},{"date":"2023-08-11","current":-0.492307,"twenty":-3.605533,"median":-2.464449,"eighty":-1.673383,"marketCap":5166973},{"date":"2023-08-18","current":-0.451047,"twenty":-3.604385,"median":-2.451581,"eighty":-1.658517,"marketCap":4733931},{"date":"2023-08-25","current":-0.474846,"twenty":-3.599792,"median":-2.429294,"eighty":-1.650503,"marketCap":4615829},{"date":"2023-09-01","current":-0.455119,"twenty":-3.59581,"median":-2.407007,"eighty":-1.641321,"marketCap":4424070},{"date":"2023-09-08","current":-0.515598,"twenty":-3.574766,"median":-2.401897,"eighty":-1.635487,"marketCap":5011970},{"date":"2023-09-15","current":-0.457243,"twenty":-3.566924,"median":-2.38362,"eighty":-1.627894,"marketCap":4444715},{"date":"2023-09-22","current":-0.50771,"twenty":-3.560315,"median":-2.374811,"eighty":-1.617598,"marketCap":4935296},{"date":"2023-09-29","current":-0.546143,"twenty":-3.551056,"median":-2.338167,"eighty":-1.605284,"marketCap":5308884},{"date":"2023-10-06","current":-0.576484,"twenty":-3.535509,"median":-2.330801,"eighty":-1.598066,"marketCap":5603822},{"date":"2023-10-13","current":-0.56637,"twenty":-3.529416,"median":-2.317858,"eighty":-1.582702,"marketCap":5505509},{"date":"2023-10-20","current":-0.529961,"twenty":-3.529416,"median":-2.309344,"eighty":-1.582674,"marketCap":5151583},{"date":"2023-10-27","current":-0.515296,"twenty":-3.529416,"median":-2.303676,"eighty":-1.573299,"marketCap":5009030},{"date":"2023-11-03","current":-0.488595,"twenty":-3.529416,"median":-2.295319,"eighty":-1.555321,"marketCap":4749485},{"date":"2023-11-10","current":-0.420732,"twenty":-3.529416,"median":-2.279706,"eighty":-1.52544,"marketCap":4089807},{"date":"2023-11-17","current":-0.49227,"twenty":-3.529416,"median":-2.266533,"eighty":-1.497359,"marketCap":3974781},{"date":"2023-11-24","current":-0.519915,"twenty":-3.529416,"median":-2.255719,"eighty":-1.484111,"marketCap":4197997},{"date":"2023-12-01","current":-1.259878,"twenty":-3.529416,"median":-2.246954,"eighty":-1.471408,"marketCap":10172748},{"date":"2023-12-08","current":-0.944716,"twenty":-3.529416,"median":-2.243626,"eighty":-1.458806,"marketCap":7628004},{"date":"2023-12-15","current":-0.760271,"twenty":-3.529416,"median":-2.242091,"eighty":-1.44978,"marketCap":6138727},{"date":"2023-12-22","current":-0.781479,"twenty":-3.529416,"median":-2.242091,"eighty":-1.42203,"marketCap":6309968},{"date":"2023-12-29","current":-0.878907,"twenty":-3.529416,"median":-2.242858,"eighty":-1.409887,"marketCap":7096639},{"date":"2024-01-05","current":-1.166178,"twenty":-3.529416,"median":-2.243626,"eighty":-1.402478,"marketCap":9416175},{"date":"2024-01-12","current":-1.113479,"twenty":-3.529416,"median":-2.241771,"eighty":-1.377273,"marketCap":8990667},{"date":"2024-01-19","current":-0.798188,"twenty":-3.529416,"median":-2.240902,"eighty":-1.367144,"marketCap":6444885},{"date":"2024-01-26","current":-0.76477,"twenty":-3.529416,"median":-2.232464,"eighty":-1.350711,"marketCap":6175051},{"date":"2024-02-02","current":-0.861041,"twenty":-3.529416,"median":-2.232464,"eighty":-1.323591,"marketCap":6952381},{"date":"2024-02-09","current":-0.832892,"twenty":-3.529416,"median":-2.232464,"eighty":-1.284479,"marketCap":6725098},{"date":"2024-02-16","current":-0.935719,"twenty":-3.529416,"median":-2.232464,"eighty":-1.19338,"marketCap":7555357},{"date":"2024-02-23","current":-0.96014,"twenty":-3.529416,"median":-2.232464,"eighty":-1.170061,"marketCap":7752543},{"date":"2024-03-01","current":-0.937004,"twenty":-3.529416,"median":-2.232314,"eighty":-1.094071,"marketCap":7565735},{"date":"2024-03-08","current":-1.015409,"twenty":-3.529416,"median":-2.232314,"eighty":-1.04266,"marketCap":8198808},{"date":"2024-03-15","current":-0.818497,"twenty":-3.529416,"median":-2.232314,"eighty":-0.985743,"marketCap":6608861},{"date":"2024-03-22","current":-1.096879,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6735639},{"date":"2024-03-28","current":-1.040493,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6389385},{"date":"2024-04-05","current":-0.805692,"twenty":-3.529416,"median":-2.232163,"eighty":-0.951971,"marketCap":4947537},{"date":"2024-04-12","current":-0.666183,"twenty":-3.529416,"median":-2.232163,"eighty":-0.937467,"marketCap":4090848},{"date":"2024-04-19","current":-0.746049,"twenty":-3.529416,"median":-2.232163,"eighty":-0.925458,"marketCap":4581287},{"date":"2024-04-26","current":-0.990316,"twenty":-3.529416,"median":-2.231918,"eighty":-0.92158,"marketCap":6081264},{"date":"2024-05-03","current":-0.938133,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5760823},{"date":"2024-05-10","current":-0.941612,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5782185},{"date":"2024-05-17","current":-0.792348,"twenty":-3.529416,"median":-2.231918,"eighty":-0.90316,"marketCap":5554316},{"date":"2024-05-24","current":-0.729366,"twenty":-3.529416,"median":-2.231918,"eighty":-0.885025,"marketCap":5112819},{"date":"2024-05-31","current":-0.711081,"twenty":-3.529416,"median":-2.231918,"eighty":-0.868111,"marketCap":4984642},{"date":"2024-06-07","current":-0.584609,"twenty":-3.529416,"median":-2.231918,"eighty":-0.841478,"marketCap":4098079},{"date":"2024-06-14","current":-0.584609,"twenty":-3.529416,"median":-2.232163,"eighty":-0.825714,"marketCap":4098079},{"date":"2024-06-21","current":-0.5184,"twenty":-3.529416,"median":-2.232314,"eighty":-0.813414,"marketCap":3633959},{"date":"2024-06-28","current":-0.373304,"twenty":-3.529416,"median":-2.233626,"eighty":-0.808757,"marketCap":2616845},{"date":"2024-07-05","current":-0.318365,"twenty":-3.529416,"median":-2.233626,"eighty":-0.804561,"marketCap":2231725},{"date":"2024-07-12","current":-1.077653,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7554290},{"date":"2024-07-15","current":-1.046662,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7337043},{"date":"2024-08-02","current":-0.618418,"twenty":-3.535509,"median":-2.215749,"eighty":-0.797123,"marketCap":4335076},{"date":"2024-08-09","current":-0.442331,"twenty":-3.535509,"median":-2.205592,"eighty":-0.792348,"marketCap":3100715},{"date":"2024-08-16","current":-1.081532,"twenty":-3.535509,"median":-2.189844,"eighty":-0.792348,"marketCap":7616606},{"date":"2024-08-23","current":-1.372962,"twenty":-3.535509,"median":-2.17772,"eighty":-0.792348,"marketCap":9668985},{"date":"2024-08-30","current":-1.058865,"twenty":-3.535509,"median":-2.174327,"eighty":-0.792348,"marketCap":7456976},{"date":"2024-09-06","current":-1.343819,"twenty":-3.535509,"median":-2.166303,"eighty":-0.792348,"marketCap":9463747},{"date":"2024-09-13","current":-1.110675,"twenty":-3.535509,"median":-2.161246,"eighty":-0.792348,"marketCap":7821844},{"date":"2024-09-20","current":-1.240199,"twenty":-3.535509,"median":-2.156951,"eighty":-0.792348,"marketCap":8734012},{"date":"2024-09-27","current":-1.246676,"twenty":-3.535509,"median":-2.145374,"eighty":-0.792348,"marketCap":8779620},{"date":"2024-10-04","current":-1.279057,"twenty":-3.535509,"median":-2.13956,"eighty":-0.792348,"marketCap":9007662},{"date":"2024-10-11","current":-1.292009,"twenty":-3.535509,"median":-2.13101,"eighty":-0.792348,"marketCap":9098879},{"date":"2024-10-18","current":-1.175437,"twenty":-3.535509,"median":-2.12822,"eighty":-0.792348,"marketCap":8277928},{"date":"2024-10-25","current":-1.20458,"twenty":-3.535509,"median":-2.123577,"eighty":-0.792348,"marketCap":8483166},{"date":"2024-10-31","current":-1.207818,"twenty":-3.535509,"median":-2.107658,"eighty":-0.792348,"marketCap":8505970},{"date":"2024-11-08","current":-1.123627,"twenty":-3.535509,"median":-2.074279,"eighty":-0.792348,"marketCap":7913060},{"date":"2024-11-15","current":-1.300862,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":9234956},{"date":"2024-11-22","current":-1.187744,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":8431916},{"date":"2024-11-29","current":-1.184209,"twenty":-3.535509,"median":-2.049939,"eighty":-0.792348,"marketCap":8406821},{"date":"2024-12-06","current":-1.131184,"twenty":-3.535509,"median":-2.033927,"eighty":-0.792348,"marketCap":8030396},{"date":"2024-12-13","current":-1.170069,"twenty":-3.535509,"median":-2.017112,"eighty":-0.792348,"marketCap":8306441},{"date":"2024-12-20","current":-1.088765,"twenty":-3.535509,"median":-2.001581,"eighty":-0.792348,"marketCap":7729256},{"date":"2024-12-27","current":-1.021601,"twenty":-3.535509,"median":-1.986209,"eighty":-0.792348,"marketCap":7252452},{"date":"2025-01-03","current":-1.039276,"twenty":-3.535509,"median":-1.976601,"eighty":-0.792348,"marketCap":7377927},{"date":"2025-01-10","current":-1.155929,"twenty":-3.529416,"median":-1.97197,"eighty":-0.792348,"marketCap":8206061},{"date":"2025-01-17","current":-0.802434,"twenty":-3.523734,"median":-1.964077,"eighty":-0.792348,"marketCap":5696562},{"date":"2025-01-24","current":-0.887273,"twenty":-3.508918,"median":-1.953718,"eighty":-0.792348,"marketCap":6298842},{"date":"2025-01-31","current":-0.816574,"twenty":-3.487384,"median":-1.94499,"eighty":-0.792348,"marketCap":5796942},{"date":"2025-02-07","current":-0.830713,"twenty":-3.464081,"median":-1.928314,"eighty":-0.792348,"marketCap":5897322},{"date":"2025-02-14","current":-0.869598,"twenty":-3.460004,"median":-1.914564,"eighty":-0.792348,"marketCap":6173367},{"date":"2025-02-21","current":-0.862528,"twenty":-3.449367,"median":-1.905104,"eighty":-0.792348,"marketCap":6123177},{"date":"2025-02-28","current":-0.795364,"twenty":-3.435067,"median":-1.886817,"eighty":-0.792348,"marketCap":5646372},{"date":"2025-03-07","current":-0.823644,"twenty":-3.423562,"median":-1.846485,"eighty":-0.790373,"marketCap":5847132},{"date":"2025-03-14","current":-0.813039,"twenty":-3.41639,"median":-1.80975,"eighty":-0.790373,"marketCap":5771847},{"date":"2025-03-21","current":-0.841318,"twenty":-3.407348,"median":-1.782714,"eighty":-0.790373,"marketCap":5972607},{"date":"2025-03-28","current":-0.866528,"twenty":-3.405471,"median":-1.77383,"eighty":-0.790373,"marketCap":7163218},{"date":"2025-04-04","current":-0.794114,"twenty":-3.378355,"median":-1.754307,"eighty":-0.790373,"marketCap":6564600},{"date":"2025-04-11","current":-0.72147,"twenty":-3.370724,"median":-1.718749,"eighty":-0.782944,"marketCap":5964089},{"date":"2025-04-17","current":-0.786365,"twenty":-3.368231,"median":-1.700232,"eighty":-0.779049,"marketCap":6500542},{"date":"2025-04-25","current":-0.822629,"twenty":-3.349519,"median":-1.687952,"eighty":-0.778595,"marketCap":6800324},{"date":"2025-05-02","current":-0.732922,"twenty":-3.335701,"median":-1.677345,"eighty":-0.767341,"marketCap":6058757},{"date":"2025-05-09","current":-0.752009,"twenty":-3.318337,"median":-1.658339,"eighty":-0.75921,"marketCap":6216537},{"date":"2025-05-16","current":-0.625327,"twenty":-3.306695,"median":-1.64132,"eighty":-0.752009,"marketCap":5995645},{"date":"2025-05-23","current":-0.623044,"twenty":-3.300954,"median":-1.631589,"eighty":-0.744363,"marketCap":5973753},{"date":"2025-05-30","current":-0.653685,"twenty":-3.291097,"median":-1.613804,"eighty":-0.737916,"marketCap":6267544},{"date":"2025-06-06","current":-0.626449,"twenty":-3.282404,"median":-1.587127,"eighty":-0.732937,"marketCap":6006396},{"date":"2025-06-13","current":-0.626449,"twenty":-3.276897,"median":-1.572151,"eighty":-0.718851,"marketCap":6006396},{"date":"2025-06-20","current":-0.607723,"twenty":-3.27413,"median":-1.559154,"eighty":-0.711081,"marketCap":5826857},{"date":"2025-06-27","current":-0.466432,"twenty":-3.268842,"median":-1.519397,"eighty":-0.698758,"marketCap":4472154},{"date":"2025-07-03","current":-0.408553,"twenty":-3.257603,"median":-1.473383,"eighty":-0.664356,"marketCap":3917215},{"date":"2025-07-11","current":-0.432386,"twenty":-3.236874,"median":-1.452959,"eighty":-0.65419,"marketCap":4145719},{"date":"2025-07-18","current":-0.463027,"twenty":-3.217218,"median":-1.430621,"eighty":-0.643472,"marketCap":4439510},{"date":"2025-07-25","current":-0.473241,"twenty":-3.2141,"median":-1.408221,"eighty":-0.637343,"marketCap":4537440},{"date":"2025-08-01","current":-0.997551,"twenty":-3.188721,"median":-1.381754,"eighty":-0.627362,"marketCap":9564533},{"date":"2025-08-08","current":-1.120117,"twenty":-3.181107,"median":-1.370141,"eighty":-0.627362,"marketCap":10739698},{"date":"2025-08-15","current":-1.000956,"twenty":-3.164793,"median":-1.351886,"eighty":-0.627362,"marketCap":9597177},{"date":"2025-08-22","current":-1.389916,"twenty":-3.149818,"median":-1.351739,"eighty":-0.627362,"marketCap":14399515},{"date":"2025-08-29","current":-1.265816,"twenty":-3.133169,"median":-1.335619,"eighty":-0.627362,"marketCap":13113844},{"date":"2025-09-05","current":-1.257543,"twenty":-3.117677,"median":-1.322798,"eighty":-0.627006,"marketCap":13028132},{"date":"2025-09-12","current":-1.14999,"twenty":-3.103112,"median":-1.30595,"eighty":-0.627362,"marketCap":11913884},{"date":"2025-09-19","current":-1.141717,"twenty":-3.087143,"median":-1.297273,"eighty":-0.627362,"marketCap":11828173},{"date":"2025-09-26","current":-0.670138,"twenty":-3.067674,"median":-1.286016,"eighty":-0.627362,"marketCap":6942623},{"date":"2025-10-03","current":-0.529492,"twenty":-3.01938,"median":-1.275424,"eighty":-0.623501,"marketCap":5485529},{"date":"2025-10-10","current":-1.442653,"twenty":-2.995922,"median":-1.267432,"eighty":-0.616672,"marketCap":14945873},{"date":"2025-10-17","current":-1.249225,"twenty":-2.91443,"median":-1.264341,"eighty":-0.616672,"marketCap":12941957},{"date":"2025-10-24","current":-1.289522,"twenty":-2.875231,"median":-1.264341,"eighty":-0.616672,"marketCap":13359440},{"date":"2025-10-31","current":-1.216987,"twenty":-2.813038,"median":-1.258586,"eighty":-0.616672,"marketCap":12607971},{"date":"2025-11-07","current":-1.031618,"twenty":-2.781244,"median":-1.253152,"eighty":-0.616672,"marketCap":10687552},{"date":"2025-11-14","current":-1.245919,"twenty":-2.740725,"median":-1.250644,"eighty":-0.616672,"marketCap":13918859},{"date":"2025-11-21","current":-1.146607,"twenty":-2.677684,"median":-1.246297,"eighty":-0.616672,"marketCap":12809385},{"date":"2025-11-28","current":-1.435516,"twenty":-2.656351,"median":-1.246297,"eighty":-0.616672,"marketCap":16036946},{"date":"2025-12-05","current":-1.471629,"twenty":-2.625475,"median":-1.246297,"eighty":-0.616672,"marketCap":16440391},{"date":"2025-12-12","current":-1.471629,"twenty":-2.589141,"median":-1.246297,"eighty":-0.616672,"marketCap":16440391},{"date":"2025-12-19","current":-1.110493,"twenty":-2.546865,"median":-1.242649,"eighty":-0.616672,"marketCap":12405939},{"date":"2025-12-26","current":-1.30009,"twenty":-2.53187,"median":-1.240895,"eighty":-0.616672,"marketCap":14524027},{"date":"2026-01-02","current":-1.209806,"twenty":-2.515486,"median":-1.23858,"eighty":-0.616672,"marketCap":13515414},{"date":"2026-01-09","current":-1.30009,"twenty":-2.498557,"median":-1.23858,"eighty":-0.616672,"marketCap":14524027},{"date":"2026-01-16","current":-1.209806,"twenty":-2.489022,"median":-1.236891,"eighty":-0.616672,"marketCap":13515414},{"date":"2026-01-23","current":-1.282033,"twenty":-2.465907,"median":-1.236891,"eighty":-0.616672,"marketCap":14322304},{"date":"2026-01-30","current":-1.182721,"twenty":-2.437573,"median":-1.23371,"eighty":-0.616672,"marketCap":13212830},{"date":"2026-02-06","current":-0.938954,"twenty":-2.392653,"median":-1.223977,"eighty":-0.616672,"marketCap":10489575},{"date":"2026-02-13","current":-0.95701,"twenty":-2.376157,"median":-1.215641,"eighty":-0.616672,"marketCap":10691297},{"date":"2026-02-20","current":-1.002153,"twenty":-2.339841,"median":-1.209806,"eighty":-0.616672,"marketCap":11195604}],"updateTime":1771873649417},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNGX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611970347","title":"Soligenix Inc. Publishes 2026 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611970347?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:09","pubTimestamp":1770930582,"startTime":"0","endTime":"0","summary":"Soligenix Inc. published a shareholder letter from President and Chief Executive Officer Dr. Christopher J. Schaber on February 12, 2026. The letter provides an update on recent progress and outlines upcoming milestones for 2026. The company is evaluating potential strategic options, including partnership and merger and acquisition opportunities. Efforts continue toward partnership in ex-U.S. markets and discussions are ongoing with potential partners. The company is advancing toward the completion of the FLASH2 confirmatory trial and is pursuing marketing authorizations for HyBryte worldwide. Additional cutaneous indications for HyBryte are also under evaluation. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL2BXd9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2610978985","title":"Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610978985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610978985?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:30","pubTimestamp":1770910222,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soligenix (SNGX – Research Report) and Boston Scient...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-soligenix-sngx-and-boston-scientific-bsx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-soligenix-sngx-and-boston-scientific-bsx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0238689110.USD","LU1983299246.USD","LU0128526141.USD","LU2242649171.HKD","LU2324357040.USD","LU0048584097.USD","XLV","LU1718418525.SGD","BK4504","LU1791710400.SGD","LU0353189763.USD","LU0528227936.USD","LU0950375773.USD","LU2362540622.SGD","XBI","LU1720051108.HKD","BSX","LU1989764748.USD","LU0251132253.USD","LU0345769128.USD","LU2506952097.USD","LU1989771016.USD","LU0823417653.USD","LU0122379950.USD","LU2491050071.SGD","BK4585","LU2244417387.USD","LU2087625088.SGD","BK4588","LU2362541273.HKD","LU0077335932.USD","SNGX","LU2506952170.USD","LABU","LU1989772923.USD","LU2362541513.USD","LU1153585028.USD","BK4137","HCSG","IE0002141913.USD","LU1989772840.SGD","LU1023059063.AUD","LU0225283273.USD","LU2506951958.HKD","LU1057294990.SGD","LU1366192091.USD","LU1720051017.SGD","SGXZ57979304.SGD","LU1791710582.SGD","BK4581"],"gpt_icon":0},{"id":"2610925232","title":"Soligenix : Continue to Evaluate Potential Strategic Options, Including, but Not Limited to, Partnership and Merger and Acquisition Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610925232?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:34","pubTimestamp":1770899684,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nFWN3Z80VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2610992525","title":"Soligenix Advances Phase 3 FLASH2 Trial for HyBryte in Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992525","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610992525?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:34","pubTimestamp":1770899664,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has provided an update on its ongoing clinical development of HyBryte  for the treatment of early-stage cutaneous T-cell lymphoma . The company is conducting the FLASH2 confirmatory Phase 3 clinical trial, which is actively enrolling patients. As of February 10, 2026, 66 out of the planned 80 patients have been enrolled. An interim analysis is planned for the second quarter of 2026, with top-line results from the trial expected in the second half of 2026. No final results have been presented yet. The FLASH2 study is designed to replicate the company's first successful Phase 3 FLASH trial, with a modification to the primary endpoint assessment period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL705Dsl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2610925486","title":"Soligenix Reports Progress on HyBryte Phase 3 Trial and Outlines 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925486","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610925486?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:31","pubTimestamp":1770899491,"startTime":"0","endTime":"0","summary":"Soligenix Inc. provided a business update highlighting recent progress and upcoming milestones. As of September 30, 2025, the company reported approximately $10.5 million in cash, not including an additional $500,000 in non-dilutive funding from New Jersey's net operating loss  sales program. Soligenix remains focused on advancing its Specialized BioTherapeutics rare disease business segment, particularly the completion of its confirmatory Phase 3 HyBryte clinical trial. The company anticipates achieving multiple key milestones through 2026 and continues to evaluate strategic options, including partnership and merger and acquisition opportunities. Additionally, Soligenix is pursuing ex-U.S. market partnerships and exploring other potential indications for its synthetic hypericin platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL2BNRvP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2605837242","title":"BRIEF-Soligenix Inc Enters Sales Agreement With Rodman","url":"https://stock-news.laohu8.com/highlight/detail?id=2605837242","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605837242?lang=en_us&edition=fundamental","pubTime":"2026-01-24 05:35","pubTimestamp":1769204106,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Enters Sales Agreement With Rodman Jan 23  - Soligenix Inc SNGX.O:SOLIGENIX INC - ENTERS SALES AGREEMENT WITH RODMAN - SEC FILINGSOLIGENIX INC - TO OFFER SHARES UP TO $3.45 MILLION - SEC FILINGSource text: [ID:n0001104659-26-006233]Further company coverage: SNGX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO1E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2601398634","title":"Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601398634","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601398634?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:36","pubTimestamp":1767882979,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has released a corporate presentation outlining its progress in developing treatments for rare diseases and public health threats. The company highlights its late-stage pipeline, which includes HyBryte  for cutaneous T-cell lymphoma with positive Phase 3 results and ongoing confirmatory studies. Other clinical-stage assets include SGX302 for psoriasis and SGX945 for Behet's disease, both with orphan designations. The presentation details significant funding from federal sources, including NIH contracts and grants, and estimates a total addressable global market potential of approximately $2 billion in annual sales across its portfolio. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8LywFp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592903090","title":"Soligenix Reports Positive Phase 2 Results for SGX945 in Behçet's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903090","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592903090?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061055,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has announced the publication of positive results from its Phase 2a proof of concept study evaluating SGX945  for the treatment of Behet's Disease in the journal Rheumatology . The study focused on patients with aphthous ulcers associated with Behet's Disease. Results demonstrated that SGX945 treatment led to improvements in oral pain, reduced duration and number of oral ulcers, and was well-tolerated with no treatment-related adverse events reported. The improvements were sustained during a follow-up period after treatment had ended. Soligenix plans to pursue a reformulation of SGX945 to enable home-based subcutaneous administration and intends to engage regulatory authorities for the design of a follow-on clinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL9FbjQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2592890306","title":"Soligenix Inc - Sgx945 Well-Tolerated With No Treatment-Related Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2592890306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592890306?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6BPNKW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2592037439","title":"Positive Clinical Results From Phase 2 Trial of Sgx945 for the Treatment of BehÇEt's Disease Published in Rheumatology (Oxford)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592037439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592037439?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6BPNKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2592296990","title":"Soligenix Announces Top-Line Results Of The Phase 2A Study Of Sgx302","url":"https://stock-news.laohu8.com/highlight/detail?id=2592296990","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592296990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:10","pubTimestamp":1765977028,"startTime":"0","endTime":"0","summary":"Dec 17 (Reuters) - Soligenix Inc ::*SOLIGENIX ANNOUNCES TOP-LINE RESULTS OF THE PHASE 2A STUDY OF SGX302 (SYNTHETIC HYPERICIN) IN PATIENTS WITH MILD-TO-MODERATE PSORIASIS*SOLIGENIX INC - OPTIMIZED GEL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nRSD4Mqw9S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592997512","title":"Soligenix Reports Positive Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997512","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997512?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974655,"startTime":"0","endTime":"0","summary":"Soligenix Inc. announced extended results from its ongoing Phase 2a clinical trial of SGX302  for the treatment of mild-to-moderate psoriasis. The extension, involving a third cohort of patients, assessed an improved topical gel formulation of the drug. The gel was designed to enhance ease of application to larger skin areas. According to the company, SGX302 gel therapy was well tolerated with no drug-related adverse events observed. Improvements were reported in multiple clinical indices, including the Investigator Global Assessment and Psoriasis Activity and Severity Index. The results from this extension have already been presented by Soligenix. The company plans to continue evaluating SGX302 in psoriasis, while it also advances a confirmatory Phase 3 trial for HyBryte in early-stage cutaneous T-cell lymphoma, with topline results for that study expected in the second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL1qsRq7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592997572","title":"Soligenix Inc - Study Confirms Sgx302 Improves Psoriasis Lesions","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997572?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592997520","title":"Soligenix Inc - Optimized Gel Formulation Shows Success in Third Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2592997520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592997520?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592699782","title":"Soligenix Announces Top-Line Results of the Phase 2a Study of Sgx302 (Synthetic Hypericin) in Patients With Mild-to-Moderate Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2592699782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592699782?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2592571997","title":"Soligenix Inc - Sgx302 Gel Therapy Well Tolerated With No Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2592571997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592571997?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:30","pubTimestamp":1765974600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4X9TPW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2589890136","title":"Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad","url":"https://stock-news.laohu8.com/highlight/detail?id=2589890136","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589890136?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:30","pubTimestamp":1764941400,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  05, 2025  (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands withinthe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200703/0/en/Soligenix-Inc-NASDAQ-SNGX-Advancing-Rare-Disease-Therapies-Positioned-at-Pivotal-Crossroad.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain",".IXIC","QLD","BK4139","TQQQ","R","03160","TM","USJW.SI","BK4099","BK4022","BK4555","TSYW.SI","USAW.SI","BK4232","BK4585","NVIW.SI","SQQQ","PSQ","QID","BK4588","BK4604","SNGX","NQmain"],"gpt_icon":1},{"id":"2588413320","title":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2588413320","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588413320?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:30","pubTimestamp":1764768600,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (\"BMW\"), one of 75+ brands withinthe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198880/0/en/Soligenix-Inc-NASDAQ-SNGX-Innovative-Platform-Provides-Novel-Treatment-for-Underserved-CTCL-Space.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","USJW.SI","NVIW.SI","BK4588","R","BK4555","TSYW.SI","QLD","TM","USAW.SI","BK4139","BK4099","03160","BK4585","PSQ","BK4022","MNQmain","TQQQ","SQQQ","QID",".IXIC","BK4604","SNGX","NQmain"],"gpt_icon":1},{"id":"2586491196","title":"Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491196","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586491196?lang=en_us&edition=fundamental","pubTime":"2025-11-25 01:52","pubTimestamp":1764006762,"startTime":"0","endTime":"0","summary":"Soligenix Inc. has released a corporate presentation outlining updates across its pipeline for rare disease treatments and public health solutions. The company highlighted progress in its Specialized BioTherapeutics segment, including the ongoing Phase 2a clinical study of SGX302 for mild-to-moderate psoriasis, with clinical success observed in two of four patients in Cohort 2. The presentation also noted the completion of a Phase 2a proof-of-concept study for SGX945 in treating aphthous ulcers in Behet's Disease, demonstrating biological efficacy and safety. Within its Public Health Solutions segment, Soligenix reported continued development of its vaccine candidates for ricin toxin, filoviruses such as Ebola and Marburg, and COVID-19, supported by ongoing government funding and collaborations. The pipeline includes multiple fast track and orphan designated products, with several candidates advancing through late-stage clinical studies and regulatory discussions. You can access the fu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5vYRK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2584946056","title":"Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte","url":"https://stock-news.laohu8.com/highlight/detail?id=2584946056","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584946056?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:35","pubTimestamp":1763555743,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced that it has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80 patient confirm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenix-completes-enrollment-of-patients-for-phase-3-study-evaluating-hybryte-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenix-completes-enrollment-of-patients-for-phase-3-study-evaluating-hybryte-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNGX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}